Controlled-release drug delivery systems in cardiovascular medicine
Abstract
Controlled-release drug delivery technology has had a significant effect on the pharmacotherapy of cardiovascular diseases. Oral and transcutaneous controlled-release systems allow relatively short-acting drugs to be administered once or twice daily with comparable therapeutic efficacy and fewer adverse reactions compared with standard formulations. They can provide decreased fluctuations in drug concentrations in plasma while possibly reducing the total amount of drug necessary for a clinical response. Techniques include the diffusion, bioerosion or degradation, and generation of osmotic pressure in orally active and transcutaneous drug delivery systems. Calcium-channel blocking agents, nitrates, beta-blocking agents, antiarrhythmic agents, clonidine, and nicotinic acid can be administered by these techniques, which have greatly influenced the application of these drugs in clinical practice.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Various nanoparticulate systems, such as lipid-based and polymeric nanoparticles, have been found effective in overcoming limitations of conventional anti-hypertensive drugs.
“Various nanoparticulate systems, such as lipid-based and polymeric nanoparticles, have been found to be effective in overcoming the limitations of conventional (immediate release) anti-hypertensive drugs.136”
From Targeted therapy in chronic diseases using nanomaterial-based drug delivery vehicles (2019) · cites this paper as [136]
The citation lists haven’t been fetched yet
References 18 · Cited by 23
- Authors
- Katz, B., Rosenberg, A., & Frishman, W. H.
- Affiliations
- Boston University (US)
- Cornell University (US)
- Albert Einstein College of Medicine (US)
- Corresponding author
- Frishman, William H.
- ORCID
- Frishman, William H.
- Venue
- American Heart Journal
- Publisher
- Elsevier BV
- Published
- 1995-02
- Volume
- 129
- Issue
- 2
- Pages
- 359-368
- ISSN
- 0002-8703 (ISSN-L)
- OpenAlex
- W2059881571
- Cited by
- 23
- References
- 18
- Citations by year
- 2024: 2 · 2023: 2 · 2021: 2 · 2019: 2 · 2018: 3 · 2017: 1 · 2014: 1 · 2012: 1
- FWCI
- 0.42
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- American Heart Journal (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Drug Solubulity and Delivery Systems
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advancements in Transdermal Drug Delivery
- Keywords
- controlled drug delivery, cardiovascular disease, oral drug delivery, transdermal drug delivery, diffusion-controlled release, bioerosion, osmotic drug delivery, calcium channel blockers, nitrate, beta-blockers, antiarrhythmic drugs, clonidine, nicotinic acid
- MeSH terms
- Administration, Cutaneous, Administration, Oral, Cardiovascular Agents, Humans, Drug Delivery Systems
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
